How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,442 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

15381. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. (Abstract)

Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. Psoriasis has been associated with an abnormal plasma lipid metabolism and diabetes mellitus possibly related to alterations in insulin secretion and sensitivity.We sought to identify lipid profile, insulin secretion, and insulin sensitivity in patients with psoriasis and healthy control patients.A cross-sectional study was performed in 44 nonobese adults, 22 with psoriasis and 22 without. The psoriasis activity (...) was evaluated by the psoriasis area and severity index. Insulin secretion was estimated using the homeostasis model analysis beta-cell function index. Insulin sensitivity was assessed with the insulin tolerance test.High-density lipoprotein cholesterol was significantly decreased in patients with psoriasis (P =.02). There were no significant differences in insulin secretion or sensitivity in patients with psoriasis compared with control patients.Patients with psoriasis had significantly decreased high

2003 Journal of American Academy of Dermatology

15382. Repeated exposure to blue light does not improve psoriasis. (Abstract)

Repeated exposure to blue light does not improve psoriasis. Increased endogenous levels of protoporphyrin IX (PpIX) have been reported in the skin of patients with psoriasis. Activation of PpIX with blue light after exogenous topical application of its precursor, aminolevulinic acid, can improve psoriasis. Light activation of endogenous PpIX for the treatment of psoriasis has never been studied.The purpose of this study was to determine the efficacy of multiple exposures to blue light (...) in patients with plaque psoriasis.A total of 17 patients with plaque psoriasis presenting increased endogenous level of PpIX were enrolled. Of the 2 identified plaques on each patient, 1 was exposed to 10 J/cm(2) of blue light from a fluorescent panel 3 times per week for 4 consecutive weeks. Plaque severity was assessed in a blinded fashion. PpIX levels were measured with in vivo fluorescence spectroscopy weekly.A single exposure to blue light induced almost complete photobleaching of PpIX

2003 Journal of American Academy of Dermatology

15383. Achilles tendinitis in psoriasis: clinical and sonographic findings. (Abstract)

Achilles tendinitis in psoriasis: clinical and sonographic findings. Involvement of the Achilles tendon is frequent in psoriatic arthritis, but it is easily missed at clinical examination.To seek evidence of Achilles tendon abnormalities by means of sonography in psoriatic patients and to correlate sonographic findings with clinical symptoms (tendon and soft-tissue swelling, pain, and difficulty in walking).Fifty-nine patients with plaque-type psoriasis (Psoriasis Area and Severity Index score

2003 Journal of American Academy of Dermatology

15384. Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. (Abstract)

Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. We studied the efficacy of granulocyte and monocyte adsorption apheresis in 2 patients with pustular psoriasis, one localized, the other generalized. Treatment with granulocyte and monocyte adsorption apheresis resulted in remarkable clearing of the skin lesions, suggesting that this therapy is a valuable tool for treating patients with intractable skin diseases attributable to activated granulocytes. We present

2003 Journal of American Academy of Dermatology

15385. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Full Text available with Trip Pro

Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. To determine if the rate of lymphoma in patients with a history of psoriasis is different from the rate of lymphoma in patients without psoriasis.Cohort study.Outpatient practices of general practitioners in the United Kingdom who contribute to the General Practice Research Database.The population studied was a sample of 10% of the patients 65 years or older (...) registered with a general practitioner contributing to the General Practice Research Database between 1988 and 1996.The rate of lymphoma in patients with psoriasis compared with the rate of lymphoma in patients without psoriasis.There were 2718 patients who had psoriasis and 105 203 patients (the reference population) who did not have psoriasis. The median follow-up time was 46 months. We noted 276 lymphomas. Patients with psoriasis had a 2.95 relative rate of developing lymphoma (95% confidence interval

2003 Archives of Dermatology

15386. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. (Abstract)

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. To critically appraise the suitability of current quality-of-life (QOL) questionnaires for psoriasis research.Computerized searches of 5 bibliographic databases. QUESTIONNAIRE SELECTION: Predefined criteria were used to identify QOL questionnaires in dermatologic studies. Two investigators independently assessed and agreed on multidimensional generic, dermatology-specific, and psoriasis (...) -specific QOL questionnaires for inclusion.Data were extracted on the internal structure, reliability, and validity of the included questionnaires.Three generic, 3 dermatology-specific, and none of the psoriasis-specific questionnaires met the inclusion criteria: the Nottingham Health Profile (NHP), the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), the Sickness Impact Profile (SIP), the Dermatology Quality of Life Scales (DQOLS), the Dermatology-Specific Quality of Life Instrument

2002 Archives of Dermatology

15387. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Full Text available with Trip Pro

Efficacy of acitretin and commercial tanning bed therapy for psoriasis. To assess the efficacy of acitretin and commercial tanning bed therapy for the treatment of moderate to severe chronic plaque-type psoriasis.Retrospective medical record review and telephone survey of subjects and prospective open-label trial.University dermatology clinic.The study population comprised 26 subjects in the retrospective study and 17 subjects in the prospective study, all with moderate to severe plaque-type (...) psoriasis.Twelve weeks of daily oral acitretin (25 mg) therapy and commercial tanning bed UV exposure (mean UV-B output of 4.7%) for 4 to 5 days per week.In the retrospective review, 19 (83%) of 23 subjects had clearance or near clearance, 2 (9%) of 23 had moderate improvement, and 2 (9%) of 23 had no improvement. Patients reported a high degree of satisfaction with the treatment. In the prospective trial, the Psoriasis Area and Severity Index (PASI) and National Psoriasis Foundation scores decreased

2003 Archives of Dermatology

15388. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Full Text available with Trip Pro

Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. To assess whether psychological distress affects treatment outcome in psoriasis.Cohort study of patients with psoriasis receiving psoralen-UV-A (PUVA) photochemotherapy.Two university hospital dermatology departments.One hundred twelve patients with chronic plaque psoriasis.We assessed clinical severity of psoriasis, psychological distress, and other potential confounders of treatment outcome (...) such as skin phototype, family history of psoriasis, and alcohol intake before starting PUVA therapy. Clinical severity of disease and response to therapy were assessed at every fourth appointment.Pathological or high-level worry was the only significant (P =.01) predictor of time taken for PUVA to clear psoriasis. Event curves of time to clearance significantly differed between high- and low-level worry groups (log rank test, 6.64; df = 1; P =.01). Patients in the high-level worry group cleared with PUVA

2003 Archives of Dermatology

15389. 308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry. Full Text available with Trip Pro

308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry. To determine the response of stubborn psoriatic plaques to the 308-nm excimer laser.Controlled study with a before-after design.A university-based clinical research center.Adult subjects with recalcitrant plaque psoriasis that have not responded to other therapies for at least 2 months.Selected psoriatic plaques were treated with the 308-nm excimer laser. One lesion was left as a control. Each plaque was treated 2 (...) times a week, with an initial dose based solely on the induration component of the modified Psoriasis Area and Severity Index score for that lesion. Subsequent treatments were twice a week with dosage increments up to 50%, based on the change in induration. Four final consolidation doses were given once the induration score was reduced to zero.Eighteen subjects were treated. There were 4 dropouts because of various scheduling problems. In the remaining 14 subjects, 44 plaques received a mean of 10

2003 Archives of Dermatology

15390. Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. (Abstract)

Normal keratinocytes express Toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Toll-like receptors (TLRs) are part of the innate immune system involved in the response to microbial pathogens. TLR2 recognizes various ligands expressed by Gram-positive bacteria, while TLR3, TLR4 and TLR5 are specific for double-stranded RNA, Gram-negative lipopolysaccharides and bacterial flagellin, respectively.To determine, firstly, whether epidermal keratinocytes (...) of normal skin express TLRs and, secondly, whether modulation of TLR expression occurs in psoriasis, an inflammatory skin disease associated with certain microorganisms such as streptococci, staphylococci and yeasts.Eight samples of normal, and 15 samples of lesional and nonlesional psoriatic skin were stained with polyclonal antibodies specific for TLR1-5 using an avidin-biotin-peroxidase technique.Epidermal keratinocytes in normal skin constitutively expressed TLR1, TLR2 and TLR5, while TLR3 and TLR4

2003 British Journal of Dermatology

15391. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. (Abstract)

Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Fumarates have been shown to be effective in psoriasis vulgaris.To find out whether successful therapy is associated with modulation of cytokines.We determined interferon (IFN)-gamma, interleukin (IL)-4 and IL-10 secretion capacities of peripheral blood mononuclear cells (PBMC) after phytohaemagglutinin stimulation, and IL-12p70 and IL-10 secretion capacities of PBMC after (...) endotoxin stimulation in psoriasis vulgaris patients during treatment with fumarates. In a cohort study, 12 patients (five men, median age 50 years; seven women, median age 46 years) with psoriasis vulgaris were followed during 24 months of fumarate treatment. In addition, we followed 14 healthy controls (six men, median age 31 years; eight women, median age 29 years) without skin diseases during 12 months to investigate possible changes in the cytokine secretion capacity of PBMC as a result of seasonal

2003 British Journal of Dermatology

15392. Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. (Abstract)

Experiences of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Psoriasis may have a severe impact on patients' quality of life (QOL) in several ways, an impact mediated by the mental or physical difficulties they have to deal with during the course of the disease and the various treatment regimens. In addition, psoriatic patients often suffer from experiences of stigmatization (EOS) related to the disease.This study was designed (...) to test the hypotheses that psoriasis patients report higher levels of stigmatization than a comparison group, and that their EOS play a role in mediating the impact of the severity of psoriasis on their QOL.One hundred patients with psoriasis (study group) and 100 patients with mixed skin problems (comparison group) were matched according to age, sex and education. All subjects answered questionnaires on EOS and QOL. A dermatologist diagnosed the diseases and measured severity scores. The Psoriasis

2002 British Journal of Dermatology

15393. Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. (Abstract)

Positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. In the 1997 revision of the International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis (JIA), a family history of psoriasis is an exclusion for the oligoarthritis category. We investigated whether psoriasis in a first or second degree relative influences the clinical expression and course of JIA (...) patients with oligoarthritis.In a cross-sectional study, consecutive oligoarticular-onset JIA patients were investigated. Clinical evaluations included confirmation of a family history of psoriasis and assessment of nail abnormalities, dactylitis, psoriatic rash, variables of JIA activity, and laboratory indicators of inflammation. Retrospective assessments included sex, onset age, disease duration, antinuclear antibodies, HLA-B27, uveitis, ocular complications, second-line therapies, intraarticular

2003 Arthritis and Rheumatism

15394. Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". (Abstract)

Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". To characterize the clinical pattern of psoriatic arthritis (PsA) sine psoriasis.Fifty-seven patients (31 men, 26 women, mean age 46.32 +/- 14.12 yrs) with undifferentiated spondyloarthropathy (SpA) were studied. Two subsets were defined: (1) 21 patients with familial psoriasis (12 men, 9 women, mean age 49.29 +/- 14.17 yrs); (2) 36 patients without familial psoriasis (19 men, 17 women, mean age 44.58 +/- 14.00 yrs (...) ). The prevalence of the following clinical variables was evaluated: low back pain, enthesopathy, dactylitis, distal interphalangeal (DIP) arthritis, spinal involvement, and discitis. In all patients the following HLA haplotypes were tested: B7, B13, B17, B18, B27, B38, Cw6, and DR7.Dactylitis and DIP arthritis were markedly present in the articular subset with familial psoriasis (p < 0.0001) that also showed a high frequency rate of HLA-Cw6 (p < 0.0001 vs controls and patients without familial psoriasis). HLA

2003 Journal of Rheumatology

15395. The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis. (Abstract)

The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis. To examine the evidence that families, where the mother has disease, carry more heritable factors and investigate the effect of maternal/paternal inheritance on phenotypic expression of disease in terms of (a) severity and outcome and (b) additional co-disorders. The children of women with ankylosing (...) spondylitis (AS) develop the disease more often than the children of men. This suggests that either women with disease carry more susceptibility factors than men or that the uterine environment/breast feeding may play a role in AS.The number of second degree relatives (i.e., grandparent, aunt/uncle) was calculated for those index patients with a mother with disease as opposed to a father. Outcome measures were compared and prevalence of secondary disorders (i.e., psoriasis, iritis, inflammatory bowel

2003 Journal of Rheumatology

15396. HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. (Abstract)

HLA antigens may influence the age of onset of psoriasis and psoriatic arthritis. To analyze whether HLA antigens may influence the age of onset of both psoriasis and psoriatic arthritis (PsA).One hundred thirty-five patients with PsA (77 men, 58 women, mean age 47 +/- 12 yrs) were analyzed. All were studied with a standard protocol and consecutively recruited to evaluate the relative contribution of HLA-Cw and HLA-B27 alleles to PsA susceptibility. Fifty patients with psoriasis alone were also (...) recruited to analyze the role of HLA-Cw genes on disease susceptibility. HLA-Cw antigens were investigated by DNA based methods (PCR-SSOP), while HLA-B27 antigen was studied using serological methods, and their frequencies were compared to 177 healthy controls.In PsA Cw6+ patients, the mean age at psoriasis onset was 23 +/- 12 years compared to 32 +/- 12 years in Cw6- patients (p = 0.012). Age of arthritis onset was 35 +/- 13 years in Cw6+ patients versus 38 +/- 12 years in Cw6- patients (p = NS

2003 Journal of Rheumatology

15397. The influence of heredity for psoriasis on the ILAR classification of juvenile idiopathic arthritis. (Abstract)

The influence of heredity for psoriasis on the ILAR classification of juvenile idiopathic arthritis. To evaluate how heredity for psoriasis influences classification according to the International League of Associations for Rheumatology (ILAR). Heredity for psoriasis is currently both an exclusion and an inclusion criterion for different types of childhood arthritis according to ILAR classification criteria.Twenty physicians in 5 Nordic countries prospectively collected data from the incident (...) cases in their catchment areas over an 18 month period beginning July 1, 1997. Clinical and serological data from the first year of disease were collected.Of the 321 patients included who could be classified according to ILAR criteria for childhood arthritis, 50 (15.6%) patients were excluded from 55 classification events and fulfilled criteria for "other arthritis 1" i.e., did not fulfill criteria for any of the other classification categories, primarily because of heredity for psoriasis

2002 Journal of Rheumatology

15398. Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. (Abstract)

Inflammatory joint manifestations are prevalent in psoriasis: prevalence study of joint and axial involvement in psoriatic patients, and evaluation of a psoriatic and arthritic questionnaire. To examine the prevalence of inflammatory manifestations, such as peripheral arthritis, axial disease, undifferentiated spondyloarthropathy (uSpA) and enthesopathies in patients with psoriasis, and to evaluate a psoriatic and arthritic questionnaire (PAQ) to identify patients with arthritis. Methods (...) regression analysis. Conclusion. We found a high prevalence of inflammatory joint/axial disease in this group of psoriatic patients. Almost half the patients with peripheral arthritis and/or axial disease had not previously been diagnosed. The PAQ did not, either as a total score or by combining questions, discriminate for arthritis in this population with psoriasis.

2002 Journal of Rheumatology

15399. A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) (RESPONSE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00096928

2004 Clinical Trials

15400. Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis

Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effects of Etanercept on Nail (...) Psoriasis and Plaque Psoriasis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00581100 Recruitment Status : Completed First Posted : December 27, 2007 Results First Posted : August 30, 2010 Last Update Posted : February 25, 2013 Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer Information

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>